List of Excipients in Branded Drug FOSAMAX PLUS D

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme Corp	FOSAMAX PLUS D	alendronate sodium and cholecalciferol	0006-0710	ANHYDROUS LACTOSE
Merck Sharp & Dohme Corp	FOSAMAX PLUS D	alendronate sodium and cholecalciferol	0006-0710	BUTYLATED HYDROXYTOLUENE
Merck Sharp & Dohme Corp	FOSAMAX PLUS D	alendronate sodium and cholecalciferol	0006-0710	CELLULOSE, MICROCRYSTALLINE
Merck Sharp & Dohme Corp	FOSAMAX PLUS D	alendronate sodium and cholecalciferol	0006-0710	CROSCARMELLOSE SODIUM
Merck Sharp & Dohme Corp	FOSAMAX PLUS D	alendronate sodium and cholecalciferol	0006-0710	GELATIN
Merck Sharp & Dohme Corp	FOSAMAX PLUS D	alendronate sodium and cholecalciferol	0006-0710	MAGNESIUM STEARATE
Merck Sharp & Dohme Corp	FOSAMAX PLUS D	alendronate sodium and cholecalciferol	0006-0710	MEDIUM-CHAIN TRIGLYCERIDES

FOSAMAX PLUS D Excipient Strategy, Generic Competition, and Commercial Opportunities

Last updated: November 8, 2026

FOSAMAX PLUS D combines once-weekly alendronate sodium with vitamin D3 in a single tablet. Its commercial value comes from dose convenience, adherence, and formulation integration rather than a complex delivery platform. The main opportunities are authorized-generic supply, private-label products, lactose-free reformulation, smaller tablets, improved stability packaging, and international expansion. Patent barriers are substantially weaker than the original combination’s clinical and regulatory barriers.

What is FOSAMAX PLUS D and how does its formulation work?

FOSAMAX PLUS D is an oral prescription tablet containing 70 mg of alendronate sodium and either 2,800 IU or 5,600 IU of cholecalciferol, also known as vitamin D3. The product is administered once weekly for osteoporosis treatment and prevention in selected postmenopausal women and men at elevated fracture risk.[1]

The product combines two conventional active ingredients:

Attribute	FOSAMAX PLUS D
Active ingredient 1	Alendronate sodium
Active ingredient 2	Cholecalciferol, vitamin D3
Alendronate strength	70 mg
Vitamin D3 strengths	2,800 IU or 5,600 IU
Dosage form	Immediate-release film-coated tablet
Dosing frequency	Once weekly
FDA product type	Prescription drug
Therapeutic category	Bisphosphonate osteoporosis therapy
Primary commercial rationale	Convenience and reduced pill burden

Alendronate has strict administration requirements. Patients must take the tablet after overnight fasting with plain water, remain upright for at least 30 minutes, and avoid food, beverages, calcium, antacids, and other oral medicines during the relevant absorption window.[1] These requirements affect both the formulation strategy and the commercial positioning.

Vitamin D3 does not eliminate the need for calcium and vitamin D management. The product label warns that patients with hypocalcemia must correct the condition before treatment and that calcium and vitamin D supplementation may be required where dietary intake is inadequate.[1]

What excipients are used in FOSAMAX PLUS D?

The labeled inactive ingredients include microcrystalline cellulose, lactose anhydrous, croscarmellose sodium, magnesium stearate, silicon dioxide, and butylated hydroxytoluene. The film coating contains conventional coating materials, including hypromellose, titanium dioxide, and talc, according to product labeling.[1,2]

Excipient	Primary formulation function	Commercial relevance
Microcrystalline cellulose	Diluent, compression aid, tablet structure	Supports direct compression and mechanical strength
Lactose anhydrous	Diluent and bulking agent	Cost-effective but creates an opportunity for lactose-free alternatives
Croscarmellose sodium	Superdisintegrant	Promotes tablet breakup and dissolution
Magnesium stearate	Lubricant	Controls ejection and manufacturing friction
Colloidal silicon dioxide	Glidant and moisture-flow aid	Improves powder flow and content uniformity
Butylated hydroxytoluene	Antioxidant	Helps protect oxidation-sensitive components, including vitamin D3
Hypromellose	Film-forming polymer	Supports coating integrity and appearance
Titanium dioxide	Opacifier and pigment	Provides a consistent white appearance
Talc	Anti-tacking and coating aid	Improves coating-process performance

The excipient system is conventional. It does not appear to create a technically difficult platform comparable with modified-release, liposomal, injectable, or biologic formulations. The main technical challenge is balancing alendronate dissolution, vitamin D3 stability, tablet robustness, and low-dose uniformity.

How strong is the FOSAMAX PLUS D formulation and excipient strategy?

The formulation has moderate technical complexity but limited long-term differentiation.

Alendronate sodium is used at a relatively high mass compared with the vitamin D3 component. The formulation therefore requires a matrix capable of accommodating the bisphosphonate dose while distributing a comparatively small quantity of vitamin D3. This creates three development priorities:

1. Uniform distribution of vitamin D3 throughout the tablet blend.
2. Protection of vitamin D3 from oxidation and light.
3. Rapid tablet disintegration and dissolution without compromising friability.

The use of an antioxidant, silicon dioxide, and a protective film coat reflects those requirements. Microcrystalline cellulose and lactose provide bulk, while croscarmellose sodium supports immediate release.

A generic manufacturer should treat vitamin D3 content uniformity as a higher-risk attribute than the nominal 70-mg alendronate dose. Vitamin D3 is present in microgram quantities, and small-scale segregation can create assay and uniformity problems. The development program should control particle size, premix order, blend time, lubricant exposure, and hopper residence time.

Moisture control also matters. Alendronate salts can have challenging powder-handling and stability characteristics, while vitamin D3 is sensitive to oxidation. A robust commercial package may require high-barrier blistering or a tightly controlled high-density polyethylene bottle with an appropriate closure and desiccant strategy.

What formulation patents protect FOSAMAX PLUS D?

The original FOSAMAX PLUS D intellectual-property position was built around the combination of alendronate and vitamin D, dosage regimens, and related osteoporosis treatment claims. The relevant exclusivity period has largely elapsed for the original U.S. product.

The active ingredients are old, well-characterized small molecules. Alendronate was previously commercialized as FOSAMAX, and vitamin D3 is a long-established nutrient and pharmaceutical ingredient. The combination therefore has less composition-of-matter strength than a newly discovered chemical entity.

The practical protection historically came from:

• Combination claims covering alendronate and vitamin D.
• Weekly dosing claims.
• Therapeutic method-of-use claims for osteoporosis.
• Product-specific formulation and manufacturing claims.
• Regulatory exclusivity associated with the original NDA.

A current competitor must distinguish between expired patent claims and any remaining listed patents or enforceable claims in the relevant jurisdiction. FDA Orange Book records, patent-term adjustments, pediatric extensions, and any withdrawn or delisted patents determine the precise U.S. position.[3]

When did FOSAMAX PLUS D lose exclusivity?

FOSAMAX PLUS D received U.S. approval in 2005 under NDA 021575.[1,3] The product’s five-year new chemical entity exclusivity did not apply in the same manner as it would for a newly discovered active ingredient because both active ingredients were previously known and marketed.

The combination’s commercial exclusivity has therefore been driven primarily by patent term, regulatory approval timing, and generic-development economics rather than by a continuing new-chemical-entity period.

Exclusivity element	Commercial assessment
New chemical entity exclusivity	Not the principal barrier for this combination
Pediatric exclusivity	Must be assessed from the FDA record for any specific extension
Composition-of-matter protection	Limited because alendronate and vitamin D3 are established actives
Combination and method patents	Historically important; many relevant terms have expired or are near expiration
Formulation patents	Potentially relevant but generally narrower than active-ingredient patents
Current market barrier	ANDA development, bioequivalence, manufacturing quality, and channel access

A generic entrant does not face biosimilar-style interchangeability requirements. FOSAMAX PLUS D is a small-molecule tablet and is subject to the ANDA pathway rather than the biologics license application or biosimilar pathway.[4]

What is the Orange Book status of FOSAMAX PLUS D?

The FDA Orange Book identifies approved drug products and, where applicable, patent and exclusivity information associated with listed products.[3] FOSAMAX PLUS D is an NDA product, not a biologic. Any current Orange Book analysis should distinguish the reference listed drug from approved ANDA products containing alendronate sodium and cholecalciferol.

For commercial planning, the key Orange Book questions are:

• Whether the reference product remains actively listed.
• Whether specific patents remain listed against the NDA.
• Whether any listed patents have expired, been delisted, or been subject to patent certification.
• Whether generic approvals use the 2,800-IU, 5,600-IU, or both strengths.
• Whether an applicant filed Paragraph IV certifications.

The presence of an Orange Book patent listing does not by itself establish that the patent is valid or infringed. An ANDA applicant may challenge a listed patent through a Paragraph IV certification, which can trigger patent litigation and, under applicable circumstances, a 30-month stay of approval.[5]

Which companies are challenging FOSAMAX PLUS D?

The principal competitive threat comes from manufacturers of generic alendronate sodium and cholecalciferol tablets rather than from biosimilar developers. Generic competition can include large U.S. suppliers, specialty generic companies, contract manufacturers, and regional pharmaceutical groups.

Public market exposure is difficult to quantify because manufacturers generally report alendronate and vitamin D products within broader generic portfolios. Merck does not generally disclose standalone FOSAMAX PLUS D revenue in a way that permits a reliable current product-level estimate.

The competitive landscape includes:

Competitor type	Product strategy	Commercial risk
Authorized generic	Same or substantially equivalent product under an authorized-generic arrangement	High price pressure with strong pharmacy acceptance
Conventional ANDA generic	Matches reference product in strength and dosage form	High substitution risk
Private-label generic	Uses a contract manufacturer and distributor brand	Strong formulary and retail-channel competition
Alendronate-only product	Competes where physicians or patients prefer separate supplementation	Moderate substitution risk
Other oral bisphosphonates	Includes risedronate and ibandronate products	Therapeutic substitution
Injectable osteoporosis drugs	Includes denosumab and zoledronic acid	Competes for patients with adherence or gastrointestinal concerns

What Paragraph IV risks exist for FOSAMAX PLUS D?

Paragraph IV risk is most relevant when an applicant seeks approval before expiry of a listed patent. The applicant asserts that the patent is invalid, unenforceable, or not infringed.[5]

For FOSAMAX PLUS D, the most likely Paragraph IV targets historically would have involved:

• Combination claims covering alendronate and vitamin D.
• Weekly administration regimens.
• Specific vitamin D dose ranges.
• Tablet composition or manufacturing claims.
• Method-of-use claims for reducing fracture risk.

The commercial value of a Paragraph IV filing is lower when remaining patents are narrow, litigation costs are high relative to expected sales, or multiple generic entrants are already approved. It is higher where one patent blocks both strengths and the reference product retains meaningful reimbursement or retail demand.

A generic sponsor also can use Paragraph III certification, wait for patent expiry, or design around a formulation claim. A design-around using different diluents, antioxidant systems, coating materials, or packaging can reduce formulation-patent exposure if the resulting product remains bioequivalent.

What excipient opportunities exist for generic FOSAMAX PLUS D?

Lactose-free tablets

Replacing lactose anhydrous with mannitol, dibasic calcium phosphate, silicified microcrystalline cellulose, or an alternative cellulose-based diluent can create a lactose-free product. The commercial opportunity is strongest in markets where lactose intolerance claims influence patient or pharmacist selection.

A lactose-free version must preserve:

• Tablet hardness.
• Disintegration time.
• Dissolution under relevant pH conditions.
• Vitamin D3 uniformity.
• Stability through expiry.
• Acceptable tablet size.

The change is commercially attractive but not automatically clinically differentiating. It must support a clear procurement, tolerability, or supply-chain proposition.

Smaller tablets

The 70-mg alendronate dose creates a substantial tablet-mass constraint. A smaller tablet may improve swallowing, but excessive compression can impair disintegration or create capping and lamination. High-density excipients, optimized granulation, or improved tooling may reduce tablet volume.

A smaller tablet could be valuable for older adults, who represent a core osteoporosis population and may have dysphagia or high pill burden. The label’s administration instructions still require the tablet to be swallowed whole with water.[1]

Improved stability packaging

Vitamin D3 oxidation and light exposure create an opportunity for differentiated packaging. Blister packs can provide unit-dose protection and support weekly adherence. Bottles may reduce cost but require strong moisture and oxygen-control performance.

Packaging opportunities include:

• Calendarized seven-day blister packs.
• High-barrier aluminum-aluminum blisters.
• Unit-dose cartons with administration reminders.
• Moisture-resistant bottles with desiccant.
• Senior-friendly closures that preserve child resistance.

Packaging changes may provide more practical commercial value than a novel excipient because adherence and stability can be communicated directly to payers, pharmacies, and patients.

Alternative antioxidant systems

A manufacturer could evaluate alternative antioxidants or oxygen-control approaches instead of butylated hydroxytoluene. Any replacement must demonstrate compatibility with alendronate, vitamin D3, the coating system, and packaging materials. The main objective is not novelty. It is stability, supply continuity, regulatory acceptability, and avoidance of proprietary formulation claims.

Improved powder processing

Continuous blending, low-shear premixing of vitamin D3, ordered mixing, and controlled particle-size engineering can improve content uniformity. These process improvements may reduce batch failures and enable smaller manufacturing runs.

The highest-value process controls are likely to involve vitamin D3 premix preparation, blend segregation, lubrication time, compression-force control, and container-closure performance.

What FDA regulatory pathway applies to a generic product?

A conventional generic version would generally use the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.[4]

The regulatory package normally requires:

• Same active ingredients.
• Same dosage form and route.
• Matching strength.
• Comparable labeling, subject to permitted differences.
• Pharmaceutical equivalence.
• Bioequivalence.
• Adequate chemistry, manufacturing, and controls documentation.
• Stability data.
• Container-closure information.
• Manufacturing-site compliance.

Alendronate presents a formulation-development challenge because oral absorption is low and administration conditions materially affect exposure. The applicant must control fasting conditions and the study design carefully. Vitamin D3 creates a separate analytical challenge because of the low dose and potential assay sensitivity.

The product is not eligible for biosimilar development because alendronate and cholecalciferol are chemically defined small molecules, not biologics.

How does FOSAMAX PLUS D compare with competing osteoporosis products?

Product category	Main advantage	Main limitation	Excipient opportunity
FOSAMAX PLUS D	Weekly combination tablet	Complex administration instructions	Smaller tablet, lactose-free formulation, adherence packaging
Alendronate-only tablet	Lower product complexity and cost	Requires separate vitamin D management	Simple low-cost generic
Risedronate	Alternative oral bisphosphonate options	Similar adherence and gastrointestinal issues	Modified dosing and packaging
Ibandronate	Monthly oral dosing available	Fracture-prevention profile differs by endpoint	Low-frequency adherence packaging
Zoledronic acid	Once-yearly intravenous administration	Infusion setting and acute-phase reactions	Limited oral-excipient opportunity
Denosumab	Six-month injection	Administration, monitoring, and discontinuation considerations	No conventional excipient competition

The combination product is most defensible where weekly convenience improves adherence and where prescribers prefer integrated vitamin D delivery. It is less defensible where payers prioritize the lowest-cost alendronate-only product or where patients use separate vitamin D supplementation.

What generic launch scenarios exist?

Low-cost commodity launch

The manufacturer uses a conventional excipient system, matches the reference tablet closely, and competes through low acquisition cost. This approach has the fastest path to broad pharmacy substitution but produces limited margin.

Premium adherence launch

The product uses calendar packaging, a smaller tablet, and patient-support materials. It may command better channel positioning but requires evidence that packaging or tablet size changes improve persistence.

Lactose-free niche launch

The product targets patients, prescribers, or health systems seeking lactose-free oral medicines. The addressable market is narrower, but the product can avoid direct price comparison if distribution is focused.

Regional or private-label launch

A contract manufacturer supplies distributors, pharmacy chains, or national tender markets. This model can scale quickly where regulatory approval and local procurement are favorable. Manufacturing qualification and supply reliability are critical.

What manufacturing and intellectual-property barriers remain?

The principal manufacturing barriers are operational rather than fundamental chemistry barriers. They include vitamin D3 uniformity, blend segregation, oxidation control, tablet robustness, dissolution consistency, and packaging stability.

Potential intellectual-property exposure can arise from:

• Exact excipient ratios.
• Antioxidant selection.
• Vitamin D3 premix methods.
• Specific tablet hardness or dissolution profiles.
• Coating composition.
• Packaging configurations.
• Manufacturing sequences.

A generic sponsor should avoid copying nonessential formulation details where a functionally equivalent alternative is available. A different excipient system can reduce patent risk, but it may increase development time and bioequivalence risk.

Geographic coverage also matters. U.S. Orange Book status does not determine freedom to operate in Europe, Canada, Japan, or emerging markets. Patent terms, regulatory data protection, compulsory licensing rules, and local substitution standards vary by jurisdiction.

Key Takeaways

• FOSAMAX PLUS D is a once-weekly combination of alendronate sodium and vitamin D3.
• Its core excipient system is conventional and includes microcrystalline cellulose, lactose anhydrous, croscarmellose sodium, magnesium stearate, silicon dioxide, and an antioxidant.
• The strongest formulation opportunities are lactose-free substitution, smaller tablets, stability-focused packaging, and adherence-oriented unit dosing.
• Vitamin D3 content uniformity and oxidation control are the principal technical risks.
• The product is a small-molecule prescription tablet and does not create biosimilar competition.
• Generic competition is more likely to be determined by ANDA execution, cost, supply reliability, and pharmacy substitution than by complex patent barriers.
• Public companies generally do not disclose standalone FOSAMAX PLUS D revenue, limiting product-level revenue exposure analysis.
• The commercial opportunity is strongest for authorized generics, private-label products, regional launches, and differentiated packaging.

FAQs

Is FOSAMAX PLUS D lactose-free?

The reference product labeling identifies lactose anhydrous as an inactive ingredient.[1] A generic manufacturer can develop a lactose-free version using alternative diluents, subject to pharmaceutical equivalence, bioequivalence, stability, and manufacturing requirements.

Can a manufacturer replace butylated hydroxytoluene in FOSAMAX PLUS D?

Yes. A manufacturer can evaluate another antioxidant system or use packaging and process controls that provide equivalent protection. The replacement must support vitamin D3 stability, product quality, and regulatory approval.

Does FOSAMAX PLUS D have a biosimilar threat?

No. FOSAMAX PLUS D contains chemically defined small molecules. Competition proceeds through generic-drug pathways, primarily ANDAs, rather than through biosimilar applications.

Is a smaller FOSAMAX PLUS D tablet commercially attractive?

Yes, particularly for older patients and patients with swallowing difficulty. The opportunity is constrained by the high mass of the 70-mg alendronate component and the need to maintain rapid dissolution and tablet integrity.

Can FOSAMAX PLUS D be converted to an over-the-counter product?

Not through a simple labeling change. Alendronate has complex administration requirements, contraindications, and safety considerations. An OTC switch would require FDA review of the proposed indication, labeling, consumer comprehension, and safe self-selection.

References

1. Merck Sharp & Dohme LLC. (2023). FOSAMAX PLUS D: Alendronate sodium and cholecalciferol tablets, prescribing information. U.S. Food and Drug Administration.

2. National Library of Medicine. (n.d.). FOSAMAX PLUS D- alendronate sodium and cholecalciferol tablet, film coated. DailyMed.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process. FDA.

5. U.S. Food and Drug Administration. (2024). Paragraph IV certification and patent-related provisions for abbreviated new drug applications. FDA.